{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:21:36Z","timestamp":1793917296020,"version":"4.8.0"},"reference-count":247,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Idiosyncratic drug-induced liver injury (iDILI) is not a uniform disease but rather includes a variety of types based on immune, autoimmune, and clinical considerations. This review attempts to close information gaps regarding the role of immunity and autoimmunity involved in the different iDILI disease types. The analysis of the current literature focusing on iDILI reveals compelling evidence of a pivotal role of immunity or autoimmunity in various types of iDILI. Among the autoimmune-triggered ones are the drug-induced autoimmune hepatitis (DIAIH) and the idiosyncratic drug-induced anti-CYP autoimmune hepatitis. In contrast, clearly immune-triggered are the human leukocyte antigen (HLA)-based immune iDILI, the immune iDILI with Stevens\u2013Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and the immune iDILI induced by immune checkpoint inhibitors (ICIs), but immune-triggered mechanisms account for only a part of the classic iDILI cases. For all these iDILI types, the use of the original or updated Roussel Uclaf Causality Assessment Method (RUCAM) allowed for confirming causality of the implicated drug, assisted by the simplified autoimmune hepatitis (AIH) score in the DIAIH cases and the Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN) score in the cases of immune-based iDILI with SJS\/TEN. All these diagnostic causality assessment algorithms are validated methods and have helped define clinical features of the different iDILI types. The first treatment goal is the cessation of the suspected drug, which alone may lead to clinical and laboratory improvement and restoration of health. However, therapy with immunosuppressive agents is often needed to treat the injury caused by immune and autoimmune processes and can lead to complete remission in all iDILI types with the exception of the classic iDILI, where only a subset of the patients achieve remission. At the molecular pathomechanistic level, there is a complex interplay mostly related to the adaptive immune system activated by the innate system. In sum, immunology and autoimmunity specifics in cases of RUCAM-ascertained iDILI types, as part of a refined classification, remain a challenging topic that can be deepened by future cases if validated diagnostic algorithms are applied.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1771858","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:06:31Z","timestamp":1785233191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["RUCAM-ascertained immunology and autoimmunity specifics of six idiosyncratic drug-induced liver injury types with refined classification: their individual complex molecular interplay"],"prefix":"10.3389","volume":"17","author":[{"given":"Rolf","family":"Teschke","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt\/Main","place":["Hanau, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2018.12.001","article-title":"Mechanisms of idiosyncratic drug-induced liver injury","volume":"85","author":"Uetrecht","year":"2019","journal-title":"Adv Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2495955","article-title":"DILI prediction in drug development: present and future","volume":"21","author":"Uetrecht","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.21037\/atm-2020-ubih-05","article-title":"Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues","volume":"9","author":"Teschke","year":"2021","journal-title":"Ann Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/livers5010008","article-title":"Immunology highlights of four major idiosyncratic DILI subtypes verified by the RUCAM: a new evidence-based classification","volume":"5","author":"Teschke","year":"2025","journal-title":"Livers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)901016","article-title":"Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions of drugs - II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge","volume":"46","author":"B\u00e9nichou","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: The update","volume":"17","author":"Danan","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131588","article-title":"Drug induced autoimmune hepatitis: Robust causality assessment using two different validated and scoring diagnostic algorithms","volume":"15","author":"Teschke","year":"2025","journal-title":"Diagnostics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/livers3030030","article-title":"Idiosyncratic DILI and RUCAM under one hat: the global view","volume":"3","author":"Teschke","year":"2023","journal-title":"Livers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310855","article-title":"Advances in idiosyncratic drug induced liver injury issues: new clinical and mechanistic analysis due to Roussel Uclaf Causality Assessment Method use. In Special Issue: Molecular Toxicology of Drug Induced Liver injury, section of Molecular Toxicology","volume":"24","author":"Teschke","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in StevensJohnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson","year":"2005","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268705","article-title":"The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome","volume":"17","author":"Naseralallah","year":"2022","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15168","article-title":"A prospective study of the incidence of drug-induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane","volume":"49","author":"Bishop","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B16","volume-title":"Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury","year":"2019"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00842","article-title":"Knowledge mapping of drug-induced liver injury: A scientometric investigation (2010-2019)","volume":"11","author":"Ke","year":"2020","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/medicines7100062","article-title":"Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993\u2013mid 2020: A comprehensive analysis","volume":"7","author":"Teschke","year":"2020","journal-title":"Medicines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018,1539077","article-title":"Review. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method","volume":"14","author":"Teschke","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000549","article-title":"Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature","volume":"7","author":"Abeles","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713562","article-title":"Metabolomic analysis of pediatric patients with idiosyncratic drug-induced liver injury according to the updated RUCAM","volume":"24","author":"And\u00fajar-Vera","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13042","article-title":"Methimazole-induced cholestasis initially obscured by an incidental finding of a large periampullary diverticulum: A case report with reference to the updated RUCAM of 2016","volume":"9","author":"Chamay","year":"2025","journal-title":"JGH Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8894498","article-title":"Epidemiology of drug- and herb-induced liver injury assessed for causality using the updated RUCAM in two hospitals from China","volume":"2021","author":"Chen","year":"2021","journal-title":"BioMed Res Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12877-020-01732-3","article-title":"Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score","volume":"20","author":"Danjuma","year":"2020","journal-title":"BMC Geriatr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2174\/2666290601666220425104715","article-title":"Severe DILI in a patient under polypharmacy including rosuvastatin: diagnostic challenges and lessons from a case report assessed using the updated RUCAM algorithm","volume":"10","author":"D\u00edaz-Orozco","year":"2022","journal-title":"Int J Gastroenterol Hepatol Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18276","article-title":"Time to use the right classification to predict the severity of checkpoint inhibitorinduced liver injury, as assessed for causality using the updated RUCAM","volume":"60","author":"Hountondji","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00067S","article-title":"Epidemiology and management of drug induced liver injury: importance of the updated RUCAM","volume":"11","author":"Kobayashi","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2028","article-title":"Drug-induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID-19 in a patient under anastrozole therapy - A case report","volume":"7","author":"Lischka","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8812983","article-title":"A Severe case of drug-induced liver injury after gemcitabine administration: a highly probable causality grading as assessed by the updated RUCAM diagnostic scoring system","volume":"2020","author":"Mascherona","year":"2020","journal-title":"Case Rep Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.966910","article-title":"Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium paraaminobenzoate as assessed for causality using the updated RUCAM","volume":"13","author":"Pl\u00fc\u00df","year":"2022","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5914593","article-title":"Drug-induced liver injury during consolidation therapy in childhood acute lymphoblastic leukemia as assessed for causality using the updated RUCAM","volume":"2022","author":"Qin","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s13019-024-02869-7","article-title":"Acute hepatotoxicity of intravenous amiodarone in a Becker muscular dystrophy patient with decompensated heart failing and ABCB4 gene mutation: as assessed for causality using the updated RUCAM","volume":"19","author":"Shi","year":"2024","journal-title":"J Cardiothorac Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.761167","article-title":"Real-world data of tigecycline-associated druginduced liver injury among patients in China: A 3-year retrospective study as assessed by the updated RUCAM","volume":"12","author":"Shi","year":"2021","journal-title":"Front Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01969-3","article-title":"Aetiology of significant liver test abnormalities in a single-centre cohort of people with cystic fibrosis exposed to elexacaftor\/tezacaftor\/ivacaftor, utilizing the updated RUCAM","volume":"83","author":"Tewkesbury","year":"2023","journal-title":"Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5090200","article-title":"Acute liver failure following a single dose of atezolizumab, as assessed for causality using the updated RUCAM","volume":"2022","author":"Tzadok","year":"2022","journal-title":"Case Rep Gastrointest Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1002126","article-title":"Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2025.102635","article-title":"Glucocorticoids accelerate the reduction of disease severity and biochemical parameters in drug-induced liver injury: Assess the causal relationship using the updated RUCAM scale","volume":"49","author":"Wang","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6331923","DOI":"10.1155\/2022\/6331923","article-title":"A case of delayed hepatic injury associated with teriflunomide use as assessed for causality using the updated RUCAM","author":"Wurzburger","year":"2022","journal-title":"Case Rep Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00816","article-title":"Comparison of different liver test thresholds for drug-induced liver injury: updated RUCAM versus other methods","volume":"10","author":"Yang","year":"2019","journal-title":"Front Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790108","article-title":"Causality evaluation of drug-induced liver injury in newborns and children in the intensive care unit using the updated Roussel Uclaf Causality Assessment Method","volume":"12","author":"Ye","year":"2021","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15575","article-title":"An analysis of silybin meglumine tablets in the treatment of drug-induced liver injury as assessed for causality with the updated Roussel Uclaf Causality Assessment Method using a nationwide database","volume":"89","author":"Zhang","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13593","article-title":"Review: Drug induced liver injury with analysis of alternative causes as confounding variables","volume":"84","author":"Teschke","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s43094-025-00788-5","article-title":"Exploring drug-induced liver injury: comprehensive insights into mechanisms and management of hepatotoxic agents","volume":"11","author":"Saleh","year":"2025","journal-title":"Futur J Pharm Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/10937404.2023.2261848","article-title":"Drug induced liver injury - a 2023 update","volume":"26","author":"Allison","year":"2023","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010015","article-title":"Treatment of drug-induced liver injury. In Special Issue: Liver Disease and Therapy, Guest Editor: Nahum M\u00e9ndez-S\u00e1nchez","volume":"11","author":"Teschke","year":"2023","journal-title":"Biomedicines"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.806249","article-title":"Pharmacotherapies for drug-induced liver injury: a current literature review","volume":"12","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17373","article-title":"Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis","volume":"57","author":"Niu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12383","article-title":"Beneficial effect of corticosteroids for patients with severe drug-induced liver injury","volume":"17","author":"Hu","year":"2016","journal-title":"J Dig Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102472","article-title":"Propensity score matching-based analysis of the effect of corticosteroids in treating severe drug-induced liver injury","volume":"48","author":"Wu","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1010605","article-title":"Introductory chapter: Glucocorticoids for acute severe drug-induced liver injury. current controversy","volume-title":"Understanding Hepatotoxicity \u2013 Causes, Symptoms and Prevention","author":"Qi","year":"2025"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073441","article-title":"Idiosyncratic drug induced liver injury, cytochrome P450 metabolic risk factors, and lipophilicity: highlights and controversies","volume":"22","author":"Teschke","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2021.605392","article-title":"Recent advances in models of immune mediated drug-induced liver injury","volume":"3","author":"Tasnim","year":"2021","journal-title":"Front Toxicol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/949157","article-title":"Innate immune cells in liver inflammation","volume":"2012","author":"Liaskou","year":"2012","journal-title":"Media Inflammation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cotox.2017.12.006","article-title":"Immune drug-induced liver disease and drugs","volume":"10","author":"Waddington","year":"2018","journal-title":"Curr Opin Toxicol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18053\/jctres.03.2017S1.001","article-title":"Immune mechanisms of idiosyncratic drug-induced liver injury","volume":"3","author":"Mak","year":"2017","journal-title":"J Clin Transl Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081974","article-title":"Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance","volume":"8","author":"Steuerwald","year":"2013","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3109\/15476910903501748","article-title":"Cytokine and autoantibody patterns in acute liver failure","volume":"7","author":"Li","year":"2010","journal-title":"J Immunotoxicol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2237154","article-title":"Serum interleukin-4 is elevated in clinical drug-induced liver injury","volume":"58","author":"Liu","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.21926\/obm.transplant.2501234","article-title":"Acute liver failure due to assumed drug induced liver injury but lack of any validated diagnostic causality algorithm: evidence by 36 cohort reports with 21,709 cases","volume":"9","author":"Teschke","year":"2025","journal-title":"OBM Transplant"},{"key":"B62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jgh3.12054","article-title":"Differential characteristics in drug-induced autoimmune hepatitis","volume":"2","author":"Mart\u00ednez-Casas","year":"2018","journal-title":"JGH Open"},{"key":"B63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ueg2.12499","article-title":"Defining characteristics and long-term prognosis of drug-induced autoimmune-like hepatitis: A retrospective cohort study","volume":"12","author":"Chung","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14195","article-title":"Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis","volume":"39","author":"Weber","year":"2019","journal-title":"Liver 21Int"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15623","article-title":"Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries","volume":"43","author":"Garc\u00eda-Cort\u00e9s","year":"2023","journal-title":"Liver Int"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.08.040","article-title":"Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study","volume":"46","author":"Licata","year":"2014","journal-title":"Dig Liver Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12532","article-title":"Natural history and outcomes in druginduced autoimmune hepatitis","volume":"46","author":"Yeong","year":"2016","journal-title":"Hepatol Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i24.2654","article-title":"Drug-induced autoimmune hepatitis: A minireview","volume":"28","author":"Tan","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.47807","article-title":"Atorvastatin-induced autoimmune hepatitis: a case report","volume":"15","author":"Tse","year":"2023","journal-title":"Cureus"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12862","article-title":"Discontinuation of immunosuppression in patients with immune-mediated drug-induced liver injury or idiopathic autoimmune hepatitis: A case-control study","volume":"7","author":"Hassoun","year":"2023","journal-title":"JGH Open"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14224","article-title":"Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs","volume":"39","author":"Valgeirsson","year":"2019","journal-title":"Liver Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.05.027","article-title":"Drug induced autoimmune hepatitis: Response to corticosteroids and lack of relapse after cessation of steroids","volume":"15","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7343805","article-title":"Menotrophin induced autoimmune hepatitis","volume":"2019","author":"Alqrinawi","year":"2019","journal-title":"Case Rep Gastrointest Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-\u03b1 antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7299","article-title":"Autoimmune-like drug-induced liver injury caused by atorvastatin and demonstration of the safety profile of pravastatin: A case report and literature review","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with druginduced liver injury","volume":"15","author":"de Boer","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J Hepatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.5223\/pghn.2018.21.4.347","article-title":"Minocycline-induced autoimmune hepatitis: a rare but important cause of drug-induced autoimmune hepatitis","volume":"21","author":"Harmon","year":"2018","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241270866","article-title":"Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction","volume":"15","author":"Fortunati","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2018.02.004","article-title":"CD4+Foxp3+CD25+\/- Tregs characterize liver tissue specimens of patients suffering from drug-induced autoimmune hepatitis: A clinical-pathological study","volume":"17","author":"Qu","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.041","article-title":"Update in clinical science: Autoimmune hepatitis","volume":"82","author":"Heneghan","year":"2025","journal-title":"J Hepatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413578","article-title":"Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms","volume":"22","author":"Sirbe","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i8.879","article-title":"Pathogenesis of autoimmune hepatitis","volume":"13","author":"Fan","year":"2021","journal-title":"World J Hepatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3791\/59174","article-title":"Induction of drug-induced, autoimmune hepatitis in BALB\/c mice for the study of its pathogenic mechanisms","volume":"159","author":"Thomas","year":"2020","journal-title":"J Vis Exp"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.5223\/pghn.2018.21.4.347","article-title":"Minocycline-induced autoimmune hepatitis: a rare but important cause of drug-induced autoimmune hepatitis","volume":"21","author":"Harmon","year":"2018","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-018-0824-x","article-title":"Two-step progression of varenicline-induced autoimmune hepatitis","volume":"11","author":"Sakakibara","year":"2018","journal-title":"Clin J Gastroenterol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199574","article-title":"Drug-induced autoimmune hepatitis by varenicline and infliximab as a continuous disease spectrum with two different flares: acute liver injury followed by hepatic autoimmunity","volume":"26","author":"Teschke","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B90","article-title":"Varenicline","volume-title":"Livertox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.006767","article-title":"Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro","volume":"34","author":"Obach","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00041.x","article-title":"Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects","volume":"48","author":"Turnheim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin-clavulanate-induced hepatitis","volume":"117","author":"Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfq374","article-title":"Genetic polymorphism and toxicology - with emphasis on cytochrome p450","volume":"120","author":"Johansson","year":"2011","journal-title":"Toxicol Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1360277","article-title":"Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review","volume":"13","author":"Myers","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bcp.2018.03.002","article-title":"Identification of enzymes responsible for dantrolene metabolism in the human liver: A clue to uncover the cause of liver injury","volume":"151","author":"Amano","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1590\/S1984-82502011000200003","article-title":"Twenty-six years of HIV science: an overview of anti- HIV drugs metabolism","volume":"47","author":"Andrade","year":"2011","journal-title":"Braz J Pharmaceut Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-6156-9","article-title":"Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism","volume":"22","author":"Landowski","year":"2005","journal-title":"Pharm Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197702050-00001","article-title":"Kinetics of hydralazine elimination","volume":"21","author":"Talseth","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"B100","article-title":"infliximab","volume-title":"Livertox. Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315411","article-title":"Depression of drug metabolizing activity in the human liver by interferon-alpha","volume":"39","author":"Okuno","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732030-00004","article-title":"Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions","volume":"32","author":"Bertz","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18030621","article-title":"Revisiting the metabolism and bioactivation of ketoconazole in human and mouse using liquid chromatography-mass spectrometry-based metabolomics","volume":"18","author":"Kim","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B104","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00003088-199732030-00004","article-title":"Metabolic conversion of methotrexate in man","volume":"74","author":"Donehower","year":"1980","journal-title":"Recent Results Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-9556(25)07851-1","article-title":"Metabolism of minocycline in humans","volume":"10","author":"Nelis","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2007.12.013","article-title":"Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity","volume":"44","author":"Wang","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01866-12","article-title":"A novel mechanism underlies the hepatotoxicity of pyrazinamide","volume":"57","author":"Shih","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S428","article-title":"Pharmacokinetics and metabolism of rifampin in humans","volume":"5","author":"Acocella","year":"1983","journal-title":"Rev Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(79)90277-4","article-title":"Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats","volume":"77","author":"Das","year":"1979","journal-title":"Gastroenterology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058107","article-title":"In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase","volume":"42","author":"Choughule","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-65","article-title":"Drug-induced liver injury due to varenicline: a case report","volume":"12","author":"Sprague","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27809","article-title":"Varenicline-induced acute liver injury with jaundice","volume":"61","author":"Mogensen","year":"2015","journal-title":"Hepatology"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M131","article-title":"Acute hepatic injury associated with varenicline in a patient with underlying liver disease","volume":"43","author":"Franck","year":"2009","journal-title":"Ann Pharmacother"},{"key":"B114","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/11537850-000000000-00000","article-title":"A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation","volume":"49","author":"Faessel","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"B115","article-title":"Varenicline","volume-title":"Statpearls [Internet]","author":"Singh","year":"2024"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00002","article-title":"Clinical pharmacokinetics and use of infliximab","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140538","article-title":"Incidence and management of infusion reactions to infliximab in a prospective real-world community registry","volume":"42","author":"Choquette","year":"2015","journal-title":"J Rheumatol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4172\/jpet.1000275","article-title":"Infliximab pharmacokinetics: an in-depth analysis","volume":"8","author":"Anwar","year":"2024","journal-title":"J Pharmacokinet Exp Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-021-03855-4","article-title":"The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease","volume":"36","author":"Mc Gettigan","year":"2021","journal-title":"Int J Colorectal Dis"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550655","article-title":"The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring","volume":"16","author":"Wadhwa","year":"2025","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175207","article-title":"The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study","volume":"12","author":"Moots","year":"2017","journal-title":"PloS One"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01482","article-title":"Drug-induced liver injury: Biomarkers, requirements, candidates, and validation","volume":"10","author":"Meunier","year":"2019","journal-title":"Front Pharmacol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/910107","article-title":"Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases","volume":"14","author":"Obermayer-Straub","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26564","article-title":"Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure","volume":"59","author":"Metushi","year":"2014","journal-title":"Hepatology"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006543","article-title":"Repeated exposure to modern volatile anaesthetics may cause chronic hepatitis as well as acute liver injury","volume":"2012","author":"Nicoll","year":"2012","journal-title":"BMJ Case Rep"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1016\/j.redox.2014.11.004","article-title":"Idiosyncratic drug-induced liver injury: Mechanistic and clinical challenges","volume":"22","author":"Jee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200202000-00003","article-title":"Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists","volume":"94","author":"Njoku","year":"2002","journal-title":"Anesth Analg"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.2.258-265.2006","article-title":"Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis","volume":"13","author":"Njoku","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1021\/tx960083q","article-title":"Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis","volume":"9","author":"Bourdi","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)39143-3","article-title":"Identification by immunoblotting of three halothane induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis","volume":"242","author":"Kenna","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5124098","article-title":"Fulminant hepatic failure in the course of an outpatient anesthetic procedure: sevoflurane among other high-risk factors","volume":"2020","author":"Cheron","year":"2020","journal-title":"Case Rep Anesthesiol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199512001-00005","article-title":"Biotransformation of sevoflurane","volume":"81","author":"Kharasch","year":"1995","journal-title":"Anesth Analg"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1097\/00000539199710000-00038","article-title":"The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humans","volume":"85","author":"Wandel","year":"1997","journal-title":"Anesth Analg"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/medicines11040009","article-title":"Human Leucocyte Antigen genetics in idiosyncratic drug-induced liver injury with evidence based on the Roussel Uclaf Causality Assessment Method","volume":"11","author":"Teschke","year":"2024","journal-title":"Medicines"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1375","article-title":"Drug-induced liver injury due to flucloxacillin: relevance of multiple Human Leukocyte Antigen alleles","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068111","article-title":"HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity","volume":"8","author":"Stephens","year":"2013","journal-title":"PloS One"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.5.717","article-title":"Coamoxiclav jaundice: clinical and histological features and HLA class II association","volume":"47","author":"O\u2019Donohue","year":"2000","journal-title":"Gut"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00090","article-title":"HLA-B*57 Allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in Ethiopians","volume":"8","author":"Petros","year":"2017","journal-title":"Front Pharmacol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1493","article-title":"Shared genetic risk factors across carbamazepine induced hypersensitivity reactions","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15054","article-title":"Association of human leukocyte antigen B*13:01 with dapsone-induced liver injury","volume":"88","author":"Devarbhavi","year":"2022","journal-title":"Brit J Clin Pharmacol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26077","article-title":"Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.66.1.12","article-title":"Flucloxacillin-induced hepatotoxicity: association with HLA-B*5701","volume":"66","author":"Teixeira","year":"2020","journal-title":"Rev Assoc Med Bras"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000209","article-title":"HLA-DRB1*16:01-DQB1*05:02 is a novel genetic risk factor for flupirtine-induced liver injury","volume":"26","author":"Nicoletti","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-020-0159-0","article-title":"HLA associations with infliximab-induced liver injury","volume":"20","author":"Bruno","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109095","article-title":"Association of HLAC*03:02 with methimazole-induced liver injury in Graves' disease patients","volume":"117","author":"Li","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.010","article-title":"Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B 35:02 as a risk factor","volume":"67","author":"Urban","year":"2017","journal-title":"J Hepatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.022","article-title":"Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort","volume":"78","author":"Daly","year":"2023","journal-title":"J Hepatol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31258","article-title":"Human leukocyte antigen B*14:01 and B*35:01 are associated with trimethoprim sulfamethoxazole induced liver injury","volume":"73","author":"Li","year":"2021","journal-title":"Hepatology"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14903","article-title":"Allopurinol hepatotoxicity is associated with human leukocyte antigen class I alleles","volume":"41","author":"Fontana","year":"2021","journal-title":"Liver Int"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2017.25.2.63","article-title":"Allopurinol-induced severe cutaneous adverse reactions: a report of three cases with the HLA-B*58:01 allele who underwent lymphocyte activation test","volume":"25","author":"Kim","year":"2017","journal-title":"Transl Clin Pharmacol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.6b00253","article-title":"Amoxicillin and clavulanate form chemically and immunologically distinct multiple haptenic structures in patients","volume":"29","author":"Meng","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.13996576.1985.tb02242.x","article-title":"HLA antigens in patients with unexplained hepatitis following halothane anaesthesia","volume":"29","author":"Otsuka","year":"1985","journal-title":"Acta Anaesthesiol Scand"},{"key":"B156","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41397-019-0092-2","article-title":"HLA- DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis","volume":"20","author":"Tangamornsuksan","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/ng.632","article-title":"A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"Singer","year":"2010","journal-title":"Nat Genet"},{"key":"B158","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2022.09.010","article-title":"Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury","volume":"78","author":"Chalasani","year":"2023","journal-title":"J Hepatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2044","article-title":"HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer","volume":"22","author":"Xu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.004","article-title":"The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine","volume":"69","author":"Fontana","year":"2018","journal-title":"J Hepatol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.tpj.6500442","article-title":"Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study","volume":"8","author":"Hirata","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"Kindmark","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102208","article-title":"Idiosyncratic hepatocellular drug-induced liver injury by flucloxacillin with evidence based on Roussel Uclaf causality assessment method and HLA B*57:01 genotype: from metabolic CYP 3A4\/3A7 to immune mechanisms","volume":"12","author":"Teschke","year":"2024","journal-title":"Biomedicines"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2024.00402","article-title":"Liver injury in immune Stevens-Johnson syndrome and toxic epidermal necrolysis: five new classification types","volume":"13","author":"Teschke","year":"2025","journal-title":"J Clin Transl Hepatol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28270","article-title":"Drug-induced liver injury associated with Stevens-Johnson syndrome\/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases","volume":"63","author":"Devarbhavi","year":"2016","journal-title":"Hepatology"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Med (Kaunas)"},{"key":"B167","article-title":"Toxic epidermal necrolysis","volume-title":"Statpearls","author":"Labib","year":"2024"},{"key":"B168","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-74698-2_195-1","article-title":"Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions","volume-title":"Oncologic Critical Care","author":"Zimmerman","year":"2019"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949520","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1046\/j.15231747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-0716-2265-0_3","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in the era of systems medicine","volume":"2486","author":"Chen","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01180-6","article-title":"Evaluation of the factors influencing mortality in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter study of 166 patients","volume":"14","author":"Erduran","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28270","article-title":"Drug-induced liver injury associated with Stevens-Johnson syndrome\/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases","volume":"63","author":"Devarbhavi","year":"2016","journal-title":"Hepatology"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_217_19","article-title":"Clinical features, risk factors, and prognostic markers of drug-induced liver injury in patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"65","author":"Zhang","year":"2020","journal-title":"Indian J Dermatol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17050714","article-title":"Case characterization, clinical features and risk factors in drug-induced liver injury","volume":"17","author":"Ortega-Alonso","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07777-1","article-title":"Clinical and liver biochemistry phenotypes, and outcome in 133 patients with anti-seizure drug-induced liver injury","volume":"68","author":"Devarbhavi","year":"2023","journal-title":"Dig Dis Sci"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12760","article-title":"Fluoxetine-induced Stevens-Johnson syndrome and liver injury","volume":"44","author":"Agrawal","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211033196","article-title":"Warfarin-induced Stevens-Johnson syndrome with severe liver injury","volume":"49","author":"Xiong","year":"2021","journal-title":"J Int Med Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00661-0","article-title":"Culprit medications and risk factors associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: population-based nested case-control study","volume":"23","author":"Gronich","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4320195","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in China","volume":"2018","author":"Yang","year":"2018","journal-title":"J Immunol Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.949520","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1111\/j.13468138.2009.00784.x","article-title":"Stevens-Johnson syndrome following occupational exposure to carbamate insecticide","volume":"37","author":"Lim","year":"2010","journal-title":"J Dermatol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit383181","article-title":"Clinicopathologic analysis of coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions","volume":"208","author":"Chung","year":"2013","journal-title":"J Infect Dis"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i1.7692","article-title":"An unusual cause of Steven-Johnson syndrome","volume":"91","author":"De Guido","year":"2020","journal-title":"Acta BioMed"},{"key":"B186","article-title":"A case of toxic epidermal necrolysis (Ten) with severe chronic ocular complications in a healthy 46-year-old woman","volume":"23","author":"Voltan","year":"2010","journal-title":"Ann Burns Fire Disasters"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2012.27.2.203","article-title":"Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.964062","article-title":"Toxic epidermal necrolysis in hepatitis A infection with acute-on-chronic liver failure: case report and literature review","volume":"9","author":"Zang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B189","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s40001-023-01142-2","article-title":"Photodistributed Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and proposal for a new diagnostic classification","volume":"28","author":"McKinley","year":"2023","journal-title":"Eur J Med Res"},{"key":"B190","article-title":"The acutely ill and hospitalized patient","volume-title":"Fitzpatrick\u2019s Color Atlas and Synopsis of Clinical Dermatology, 9e","author":"Wolff","year":"2012"},{"key":"B191","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/pds.3937","article-title":"Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry","volume":"25","author":"Diphoorn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3212","article-title":"Drug-induced Stevens-Johnson syndrome: case series from tertiary care centre in Gujarat","volume":"21","author":"Bang","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i1.7692","article-title":"An unusual cause of Steven-Johnson syndrome","volume":"91","author":"De Guido","year":"2020","journal-title":"Acta BioMed"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12819","article-title":"Non-drug-induced Stevens-Johnson syndrome successfully treated with high-dose i.v. immunoglobulin","volume":"42","author":"Nozaki","year":"2015","journal-title":"J Dermatol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319894469","article-title":"Multidisciplinary care in Stevens-Johnson syndrome","volume":"11","author":"Shanbhag","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.12809\/hkmj2210131","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Hong Kong","volume":"30","author":"Cheung","year":"2024","journal-title":"Hong Kong Med J"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Res"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2025.05.002","article-title":"Updates in the pathogenesis of SJS\/TEN","volume":"74","author":"Justice","year":"2025","journal-title":"Allergol Int"},{"key":"B199","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s40001-025-02664-7","article-title":"Recent developments in the research of Stevens-Johnson syndrome and toxic epidermal necrolysis: pathogenesis, diagnosis and treatment","volume":"30","author":"Yao","year":"2025","journal-title":"Eur J Med Res"},{"key":"B200","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ajd.14329","article-title":"A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"65","author":"Stewart","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1046\/j.1365-2133.1996.d01-1111.x","article-title":"Photo-induced toxic epidermal necrolysis caused by clobazam","volume":"135","author":"Redondo","year":"1996","journal-title":"Br J Dermatol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000248385","article-title":"An unusual combination of phototoxicity and Stevens-Johnson syndrome due to antimalarial therapy","volume":"178","author":"Ortel","year":"1989","journal-title":"Dermatologica"},{"key":"B203","article-title":"Stevens-Johnson syndrome secondary to carbamazepine mediated by photosensitivity","volume":"17","author":"Su\u00e1rez Moro","year":"2000","journal-title":"Med Interna"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C271","article-title":"Photo-induced Stevens-Johnson syndrome due to sulfasalazine therapy","volume":"37","author":"Borr\u00e1s-Blasco","year":"2003","journal-title":"Ann Pharmacother"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2005.00149.x","article-title":"A case of toxic epidermal necrolysis with lesions mostly on sunexposed skin","volume":"21","author":"Mansur","year":"2005","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.02704.x","article-title":"Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis","volume":"33","author":"Callaly","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2010.09.002","article-title":"Toxic epidermal necrolysis after sun-exposure probably due to lamotrigine and chlorpromazine","volume":"3","author":"Huang","year":"2010","journal-title":"Asian J Psychiatr"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.13","article-title":"Progression of toxic epidermal necrolysis after tanning bed exposure","volume":"147","author":"Gatson","year":"2011","journal-title":"Arch Dermatol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.02.033","article-title":"Photo-induced Stevens-Johnson syndrome","volume":"71","author":"Moghaddam","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13278","article-title":"Photo-distributed Stevens-Johnson syndrome associated with oral itraconazole","volume":"55","author":"Eloranta","year":"2016","journal-title":"Int J Dermatol"},{"key":"B211","first-page":"32","article-title":"Photodistributed Stevens-Johnson syndrome associated with lamotrigine","volume":"59","author":"Dean","year":"2018","journal-title":"Australas J Dermatol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jdcr.2021.05.015","article-title":"Photodistributed toxic epidermal necrolysis in association with lamotrigine and tanning bed exposure","volume":"14","author":"Russomanno","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000993","article-title":"Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome\/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review","volume":"24","author":"Ogiji","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B214","article-title":"Stevens-Johnson syndrome","volume-title":"Statpearls","author":"Oakley","year":"2023"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.651247","article-title":"Pathogenesis of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis with severe ocular complications","volume":"8","author":"Ueta","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000914","article-title":"New insights into the diagnosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"23","author":"Saito","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b17-00207","article-title":"Effect of infectious diseases on the pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"40","author":"Okamoto-Uchida","year":"2017","journal-title":"Biol Pharm Bul"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620950831","article-title":"The Role of IL-13, IL-15 and granulysin in the pathogenesis of Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis","volume":"27","author":"Sadek","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"B219","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","article-title":"Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management","volume":"25","author":"Shah","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2024.2344664","article-title":"mRNA expression levels of cytochrome P450 CYP1A2, CYP3A4, and CYP3A5 in the epidermis: a focus on individual differences among Japanese individuals","volume":"54","author":"Makihara","year":"2024","journal-title":"Xenobiotica"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091408","article-title":"Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies","volume":"17","author":"Mc Neil","year":"2025","journal-title":"Cancers"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16198","article-title":"Immune-mediated liver injury from checkpoint inhibitor: an evolving frontier with emerging challenges","volume":"45","author":"Dara","year":"2025","journal-title":"Liver Int"},{"key":"B226","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitorinduced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.cgh.2023.12.008","article-title":"Cholangitis induced by immune checkpoint inhibitors: analysis of pharmacovigilance data","volume":"22","author":"Meunier","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1077468","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and futures perspectives","volume":"13","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1657332","article-title":"Treatment experience in managing severe immune-mediated hepatotoxicity induced by immune checkpoint inhibitors","volume":"15","author":"Cao","year":"2025","journal-title":"Front Oncol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.984940","article-title":"Liver injury during durvalumab based immunotherapy is associated with poorer patient survival: A retrospective analysis","volume":"12","author":"Swanson","year":"2022","journal-title":"Front Oncol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2023.00124","article-title":"Development and validation of a clinical risk score to predict immune-mediated liver injury caused by sintilimab: assessed for causality using updated RUCAM","volume":"11","author":"Zheng","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102514","article-title":"Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development","volume":"114","author":"Regev","year":"2020","journal-title":"J\u00a0Autoimmun"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00105","article-title":"Immunotherapy-induced hepatotoxicity: A review","volume":"10","author":"Da Cunha","year":"2022","journal-title":"J Clin Trans Hepatol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B238","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) V 5.0\n          \n          \n          2017"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.6098","article-title":"The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials","volume":"22","author":"Colevas","year":"2004","journal-title":"J Clin Oncol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01109-4","article-title":"Drug-induced liver injury: Highlights and controversies in the recent literature","volume":"44","author":"Clinton","year":"2021","journal-title":"Drug Saf"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-related hepatitis: real-world experience from a tertiary centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020101","article-title":"Checkpoint inhibitors and hepatotoxicity","volume":"9","author":"Malnick","year":"2021","journal-title":"Biomedicines"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: A review","volume":"27","author":"Remash","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1159\/000509081","article-title":"Mechanisms of immune-related complications in cancer patients treated with immune checkpoint inhibitors","volume":"106","author":"K\u00f6nig","year":"2021","journal-title":"Pharmacology"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-01019-7","article-title":"Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management","volume":"22","author":"Triantafyllou","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i48.5433","article-title":"Checkpoint inhibitors: What gastroenterologists need to know","volume":"24","author":"Ahmed","year":"2018","journal-title":"World J Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:06:39Z","timestamp":1785233199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1771858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":247,"alternative-id":["10.3389\/fimmu.2026.1771858"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1771858","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1771858"}}